MicroStockProfit.com announces an investment report featuring biopharmaceutical company Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.microstockprofit.com/ads/HEB
Hemispherx Biopharma Inc. (HEB) is a developer, maker and distributor of natural immune system drug therapies for the treatment of a variety of viral and immune-based disorders. The Company's new drug therapies include Ampligen, as well as Alferon N Injection. Ampligen is currently under early clinically development for the treatment of Chronic Fatigue Syndrome (CFS). Ampligen's applications also include its use as an adjuvant for the development of therapeutic and preventative vaccines. The Company's Alferon N product is used as an indicator for genital warts. Alferon LDO is currently under development for treating and/or preventing influenza and viral diseases.
Message Board Search for HEB: http://www.boardcentral.com/boards/HEB
In the report, the analyst notes:
"The pharmaceutical industry has underperformed the DJIA by nearly 50% from the market lows of March 9, 2009. Generally, pharmaceutical drug sales tend to be more inelastic during economic slowdowns, but are also much dependent on consumers ability to pay without company-sponsored or other third-party medical plans during periods of high unemployment.
"In the case of HEB, however, successful monetization of its product line lies in the Company's most timely development of its drug candidate, Ampligen, an experimental therapeutic for the H5N1 virus. The PolyI:PolyC12U has been noted by the publication, Therapeutics and Clinical Risk Management, as the lead adjuvant candidate for mucosal vaccines. The publication also mentioned Ampligen was "extremely important" in further studies, as the drug produces "cross-protection" against variant influenza viruses."